sci-hub.st 参考文章(22)
Se Hoon Park, Yuna Lee, Sang Hoon Han, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Yeon Ho Park, Jeong Nam Lee, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, None, Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma BMC Cancer. ,vol. 6, pp. 3- 3 ,(2006) , 10.1186/1471-2407-6-3
A.A. Dunk, S.C. Scott, P.J. Johnson, W. Melia, A.S.F. Lok, I. Murray-Lyon, R. Williams, H.C. Thomas, Mitozantrone as single agent therapy in hepatocellular carcinoma Journal of Hepatology. ,vol. 1, pp. 395- 404 ,(1985) , 10.1016/S0168-8278(85)80777-7
Ghassan K. Abou-Alfa, Philip Johnson, Jennifer J. Knox, Marinela Capanu, Irina Davidenko, Juan Lacava, Thomas Leung, Bolorsukh Gansukh, Leonard B. Saltz, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. ,vol. 304, pp. 2154- 2160 ,(2010) , 10.1001/JAMA.2010.1672
Ching‐Lung Lai, Anna Suk‐Fong Lok, Pui‐Chee Wu, Gerald Chee‐Bunn Chan, Hsiang‐Ju Lin, None, Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. ,vol. 62, pp. 479- 483 ,(1988) , 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, Karin Burock, Jessie Zou, Dimitris Voliotis, Zhongzhen Guan, None, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology. ,vol. 10, pp. 25- 34 ,(2009) , 10.1016/S1470-2045(08)70285-7
Kerstin Schütte, Lars Zimmermann, Jan Bornschein, Antal Csepregi, Ricarda Rühl, Jens Ricke, Peter Malfertheiner, Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion. ,vol. 83, pp. 275- 282 ,(2011) , 10.1159/000320377
Violaine Ozenne, Valerie Paradis, Simon Pernot, Corinne Castelnau, Marie-Pierre Vullierme, Mohamed Bouattour, Dominique Valla, Olivier Farges, Françoise Degos, Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology & Hepatology. ,vol. 22, pp. 1106- 1110 ,(2010) , 10.1097/MEG.0B013E3283386053
M Connock, J Round, S Bayliss, S Tubeuf, W Greenheld, D Moore, Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technology Assessment. ,vol. 14, pp. 17- 21 ,(2010) , 10.3310/HTA14SUPPL1/03
Winnie Yeo, Tony S Mok, Benny Zee, Thomas WT Leung, Paul BS Lai, Wan Y Lau, Jane Koh, Frankie KF Mo, Simon CH Yu, Anthony T Chan, Pun Hui, Brigette Ma, Kwok C Lam, Wing M Ho, Herman T Wong, Amanda Tang, Philip J Johnson, None, A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma Journal of the National Cancer Institute. ,vol. 97, pp. 1532- 1538 ,(2005) , 10.1093/JNCI/DJI315